Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01467934 · ClinicalTrials.gov registry record
FeverText: Assessing Fever Rates After Vaccination During the 2011-12 Influenza Season Using Text Messaging
A clinical trial of Fever, sponsored by Columbia University.
- Completed
- Registry status
- 530
- Enrollment target
- 2
- Study locations
NCT01467934: Completed study of Fever, sponsored by Columbia University.
NCT01467934 is a study of Fever that has completed, run by Columbia University. The registered enrollment target is 530 participants, roughly in line with the 570-participant average among 18 other Fever trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01467934, a study of Fever, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 530 participants
- Enrollment target
- 2
- Study locations
Study Summary
In this study, the investigators will prospectively assess fever rates and other associated vaccine adverse events in 6-23 month old patients during days 0-7 after administration of trivalent inactivated influenza vaccine (TIV) and 13-valent pneumococcal conjugate vaccine (PCV13) concomitantly compared to those who receive trivalent inactivated influenza vaccine (TIV) or 13-valent pneumococcal conjugate vaccine (PCV13) administered non-concomitantly. The investigators hypothesize that fever rates will be significantly higher during the 0-1 days after vaccination when inactivated influenza vaccine (TIV) and 13-valent pneumococcal conjugate vaccine (PCV13) are given concomitantly than when TIV or PCV13 is administered non-concomitantly.
Conditions Studied
Study Locations (2)
Georgia
- Centers for Disease Control and Prevention - Atlanta
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-06 |
What the finished NCT01467934 record still lists
NCT01467934 is an observational study that tracks outcomes without assigning an intervention. The registered 530 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 570-participant average among 18 other Fever trials with a reported enrollment target.
The record links to 1 condition, with Fever appearing as the primary indexed condition, and to 0 interventions.
NCT01467934 reports a single indexed study location in Georgia, New York.
Frequently Asked Questions
What is clinical trial NCT01467934 about?
NCT01467934 is a clinical study titled "FeverText: Assessing Fever Rates After Vaccination During the 2011-12 Influenza Season Using Text Messaging". In this study, the investigators will prospectively assess fever rates and other associated vaccine adverse events in 6-23 month old patients during days 0-7 after administration of trivalent inactivated influenza vaccine (TIV) and 13-valent pneumococcal conjugate vaccine (PCV13) concomitantly compa...
What is the current status of trial NCT01467934?
This trial is currently completed. The enrollment target is 530 participants. The study started on 2011-11. Estimated completion is 2012-06.
What conditions does trial NCT01467934 study?
This clinical trial studies the following conditions: Fever.
Who is sponsoring clinical trial NCT01467934?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01467934 being conducted?
This trial has 2 study locations across Georgia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fever
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01467934's enrollment target sits among peer trials
530 4th of 18 higher than 15 of 18 other Fever trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fever trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TriVerity™ for Improved Management of Emergency Department (ED) Patients With Suspected Infections
RECRUITING · NA
-
Remote Temperature Monitoring of Patients At Risk for Developing Fever
RECRUITING · NA
-
Prescription Antipyretics to Decrease Unscheduled Return Visits In A Pediatric Emergency Department
RECRUITING · NA
-
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
RECRUITING
-
Safety of RSV Preventive Monoclonal Antibody
RECRUITING · Phase 4
-
Tympanic Thermometer Study
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06646276 · 530 participants · Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- NCT06703476 · 530 participants · Phase 3
A Study of Surgical Techniques During Cystectomy
- NCT06880744 · 530 participants · Phase 3
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
- NCT07138040 · 530 participants · NA
Re-Engaging AYA Survivors in Cancer-Related Healthcare
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia